Monoclonal Antibodies Market Size, Value, Share, Segment 2028

The monoclonal antibodies market is projected to reach US$ 243.05 billion by 2028 from US$ 111.01 billion in 2021; it is expected to grow at a CAGR of 11.8% from 2021 to 2028.

The increasing prevalence of cancer and other chronic diseases, and a tremendous rise in COVID-19 cases across various regions are the key factors fueling the market growth. According to World Cancer Research Fund and American Institute for Cancer, in 2020, ~18.1 million cancer cases were recorded, including 9.3 million cases in men and 8.8 million cases in women. The use of monoclonal antibodies in the treatment of various types of cancer is still in phases 2 and phase 3 trials.

North America is likely to continue its dominance in the monoclonal antibodies market during 2021–2028. The US holds the largest share of the market in this region and is expected to continue to be a dominant shareholder in the market during the forecast period. According to the statistics released by Globocan 2020, ~1,806,590 new cases of cancer were diagnosed in the US and ~606,520 people died due to this disease. As per a report by the US Department of Commerce, its National Institute of Standards and Technology (NIST) announced the funding of US$ 153 million to the National Institute for Innovation in Manufacturing Biopharmaceuticals. Additionally, the FDA has been extending support for the development of monoclonal antibodies during COVID-19 prevalence.

 

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Monoclonal Antibodies Market: Strategic Insights

Monoclonal Antibodies Market

• 
  CAGR (2021 - 2028)

  11.8%
• Market Size 2021
  US$ 111.01 Billion
• Market Size 2028
  US$ 243.05 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• Novartis AG
• Pfizer Inc
• GlaxoSmithKline plc
• Amgen Inc
• Daiichi Sankyo Company Limited
• F Hoffmann La Roche AG
• AstraZeneca
• Elli Lilly and Company
• Bayer AG

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Source

• Human
• Humanized
• Chimeric
• Murine

Production Method

• In-Vitro and In-Vivo

Indication

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Inflammatory Diseases
• Microbial Diseases

Application

• Therapeutic Applications
• Diagnostic Applications
• Research Applications

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Insights

Significant Rise in Prevalence of Cancer and Other Chronic Diseases Drives Market Growth

As per the American Cancer Society report, ~16.9 million individuals with a history of cancer were residing in the US as of January 2019. By January 2030, the population of cancer survivors is estimated to rise to 22.1 million due to the growth and aging of the population alone. Therefore, with the growing prevalence of cancer and other chronic diseases, the demand for biologics, such as monoclonal antibodies (mABs), has also surged. Being principal components of many therapeutic regimens and cost-effectiveness treatments, biologics play a key role in cancer treatment.

Source-Based Insights

Based on the source, the monoclonal antibodies market is segmented into murine, chimeric, human, and humanized. The human segment is estimated to account for the largest market share during 2021–2028. The market growth of this segment is attributed to the rise on account of the integration of human monoclonal antibodies for the treatment of various kinds of infectious diseases. For instance, Regeneron launched FDA approved antibody cocktail casirivimab and imdevimab together for use in COVID-19. The drug has received Emergency Use Authorization (EUA) from FDA. It is used for the treatment of mild to moderate COVID-19 in adults as well as in pediatric patients at least 12 years of age and weighing at least 40kg. Moreover, an increase in their use in various chronic diseases and employment of advanced genetic engineering technology are among the significant factors driving the market segment's growth.

Indication-Based Insights

Based on indication, cancer, autoimmune diseases, inflammatory diseases, infectious disease, microbial disease, and others. The cancer segment would dominate the market in the coming years. Advancements related to the therapeutic application of monoclonal antibodies have enabled their successful implementation in the treatments of various cancer types, such as breast cancer, lung cancer, and colon cancer. Drugs based on these antibodies help in flagging cancer cells, triggering cell-membrane destruction, blocking immune system inhibitors, and so on. The FDA, in June 2020, approved two drugs—olaparib and rucaparib for the treatment of prostate cancer. The drug is especially effective among men with prostate cancer conditions that have spread or metastasized and has stopped responding to standard hormone treatments, i.e., castration-resistant disease condition.

End-User-Based Insights

By end-user, the monoclonal antibody market is segmented into hospitals, research institutes, and others. The hospital segment holds the largest market share owing to the increasing adoption mABs as a preferred line of treatment, especially for cancer treatment.

 

Companies operating in the monoclonal antibodies market adopt the product innovation strategy to meet the evolving customer demands across the world, which also permits them to maintain their brand name in the global market.

Monoclonal Antibodies Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Monoclonal antibodies Market - Segmentation

Based on the source, the monoclonal antibodies market is segmented into human, humanized, chimeric, and murine. By production method, the market is segmented into in-vitro and in-vivo. The monoclonal antibodies market, by indication, is further segmented as cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, and others. By application, the market is subsegmented as therapeutic applications, diagnostic applications, and research applications. Furthermore, based on end-user, the market is segmented into hospitals, others, and research institutes..

Monoclonal antibodies Market - by Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA
• South and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of SCAM

Company Profiles

• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Amgen, Inc
• Daiichi Sankyo Company, Limited
• F. Hoffmann-La Roche AG
• AstraZeneca
• Elli Lily and Company
• Bayer AG
• Bristol-Myers Squibb Company